TAIPEI MEDICAL UNIVERSITY

Far Eastern Memorial Hospital in New Taipei City administered Taiwan's first dose of Kisunla (donanemab), a new Alzheimer's drug that targets underlying disease causes rather than just symptoms.

• SL Bio, a clinical-stage biomedical company developing cellular and gene therapies, has entered a definitive business combination agreement with Horizon Space Acquisition II Corp., with the combined entity to be listed on Nasdaq. • The company's proprietary platforms include next-generation immunotherapies such as Armed-T and Gamma Delta T cell technologies targeting blood cancers, pancreatic cancer, and brain cancer with improved safety and accessibility. • Beyond oncology, SL Bio is advancing regenerative applications using cow milk-derived exosomes and plant extracts for skin and hair care products, with established commercial distribution across Asia.

Ludwig Cancer Research scientists developed PLT012, a humanized antibody that blocks the CD36 fat transporter to restore immune function in tumors that exploit fat metabolism for immune evasion.

Taipei Medical University and MSD Taiwan have signed a groundbreaking Memorandum of Understanding to collaborate across six key areas, marking the first large-scale alliance between a global pharmaceutical company and a medical university in Taiwan.

Avance Clinical, a global Contract Research Organization, has signed Memorandums of Understanding with four premier Taiwanese medical institutions, strengthening its GlobalReady model for biotech companies.

A comprehensive analysis of National Health Interview Survey data reveals approximately 2.99 million US adults with asthma report cost-related medication non-adherence, despite declining trends over the past decade.